Igf-1 crystal, composition, method of treating mammals suffering from agonist dysfunction, crystallization of igf-1, crystalline igf-1, identification methods of indirect igf-1 agonists, co-crystalline complex , igf-1 three-dimensional structure determination method, machine readable data storage medium, igf-1 crystal, igf-1 three-dimensional structure use method, igf-1 agonist or antagonist identification method, compound design method, peptidomimetic identification method, method for determining at least a three-dimensional structure part of a molecular complex, method for assessing the ability of a chemical entity to associate with igf-1, chemical entity, derivative of heavy atom, method of experimental or computational evaluation of a chemical entity and use of a composition

摘要

"CRYSTAL FORMED BY IGF-1, COMPOSITION, METHOD OF TREATMENT OF MAMMALS SUFFERING FROM AGONIST Dysfunction, CRYSTALIZATION METHOD OF IGF-1, IGF-1 CRISTICAL IDENTIFICATION METHODS CRYSTALINE, IGF-1 THREE-DIMENSIONAL STRUCTURE DETERMINATION METHOD, MACHINE-LEGIBLE DATA STORAGE, IGF-1 CRYSTAL, IGF-1 THREE-DIMENSIONAL METHOD OF IDENTIFICATION OR IDENTIFICATION METHOD OF METHOD , COMPOSITE DESIGN METHOD, PEPTIDOMIMETIC IDENTIFICATION METHOD, METHOD OF DETERMINING AT LEAST ONE PART OF A MOLECULAR COMPLEX, ASSESSMENT OF THE ENDIFIED CAPACITY ASSESSMENT. HEAVY ATOM DERIVATIVE, EXPERIMENTAL OR COMPUTER ASSESSMENT METHOD OF A CHEMICAL ENTITY AND USE OF A COMPOSITION ". Crystalline IGF-1 is supplied along with a method for its production. Crystallization of IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitate to form mixture; and crystallization of the mixture, optionally also recrystallization and isolation of crystalline IGF-1. In addition, a method of identifying indirect IGF-1 agonists is provided, which uses detergent as a standard for the level of inhibition of IGFBP-1 or IGFBP-3 binding to IGF-1 and / or use of pockets coordinates. IGF-1 binding to which a possible indirect agonist binds to structure-based drug design.